<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00248807</url>
  </required_header>
  <id_info>
    <org_study_id>B3346-V</org_study_id>
    <secondary_id>00517</secondary_id>
    <nct_id>NCT00248807</nct_id>
  </id_info>
  <brief_title>A Study of Blood Pressure and Blood Supply to the Brain in Persons With a Spinal Cord Injury.</brief_title>
  <official_title>Systemic Hemodynamics and Cerebral Blood Flow in Persons With Tetraplegia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how blood pressure and blood flow are controlled
      during head-up tilt in a semi-upright position. In this investigation we are studying blood
      pressure and blood flow to the brain, with and without a medication which lowers blood
      pressure (Vasotec). We will determine how persons with a spinal cord injury are able to
      maintain blood flow to the brain (not get dizzy) as they assume a more upright position and
      their blood pressure decreases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals with tetraplegia lack normal sympathetic nervous system regulation of blood
      pressure and, therefore, relative hypotension is a common occurrence. This hypotension may be
      more pronounced with postural stress. Loss in mental acuity and sometimes even consciousness
      is an associated symptom of postural hypotension in individuals with tetraplegia.

      There is some evidence to suggest that although mean arterial blood pressure (MAP) is
      relatively low in these individuals, middle cerebral arterial blood flow (CBF) may be
      maintained. Consequently, individuals with chronic tetraplegia often compensate and are
      stable in the seated upright position.

      Autoregulation of CBF has been defined as the stability of cerebral blood flow throughout a
      range of systemic blood pressures (MAP). This proposal will examine systemic hemodynamics and
      middle cerebral artery blood flow during HUT with and without Vasotec, an angiotensin II
      inhibitor. By partially or completely ablating the renin-angiotensin system, which is
      postulated to play a major role in blood pressure regulation, the potential dissociation
      between systemic blood pressure and middle cerebral artery blood flow, in individuals with
      tetraplegia, may be demonstrated. The aim is to determine whether persons with chronic
      tetraplegia are able to maintain similar CBF, or similar CBF changes, as able-bodied controls
      despite a greater decrease in MAP to the same hypotensive challenge. The relationship between
      MAP and CBF has not been defined in this population. Understanding this relationship may lead
      to improved screening and treatment for prevention of postural hypotension in persons with
      tetraplegia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>acute testing</time_frame>
    <description>Systolic blood pressure during head-up tilt in subjects with spinal cord injury without drug intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebral Blood Flow</measure>
    <time_frame>acute testing</time_frame>
    <description>Measurement of middle cerebral artery blood flow velocity supine and during head-up tilt</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Orthostatic Hypotension</condition>
  <condition>Spinal Cord Injuries</condition>
  <arm_group>
    <arm_group_label>ARM 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Head-up tilt maneuver without drug in subjects with spinal cord injury</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Head-up tilt maneuver without drug in able-bodied controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Head-up tilt maneuver with an angiotensin converting enzyme inhibitor (1.25 mg enalaprilat) in subjects with spinal cord injury</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Head-up tilt maneuver with an angiotensin converting enzyme inhibitor (1.25 mg enalaprilat) in able-bodied controls.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.25 mg enalaprilat IV</intervention_name>
    <description>an angiotensin converting enzyme (ACE) inhibitor given to lower blood pressure (BP) and measure cerebral blood flow (CBF)</description>
    <arm_group_label>ARM 2</arm_group_label>
    <arm_group_label>ARM 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Head up tilt (HUT)</intervention_name>
    <description>45 degree head-up tilt to lower blood pressure and measure cerebral blood flow.</description>
    <arm_group_label>ARM 1</arm_group_label>
    <arm_group_label>ARM 3</arm_group_label>
    <arm_group_label>ARM 2</arm_group_label>
    <arm_group_label>ARM 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Duration of spinal cord injury (SCI) at least 1 year

          -  Level of SCI C4-8 and T6 and below

          -  matched non-SCI subjects

          -  Chronological age between 18-65 years

          -  Euhydration: Subjects will be instructed to avoid caffeine and alcohol and to maintain
             normal salt and water intake for several days prior to study.

        Exclusion Criteria:

          -  Known heart and/or blood vessel disease

          -  Dehydration

          -  High blood pressure

          -  Kidney disease

          -  Diabetes mellitus

          -  Prescribed ACE inhibitors

          -  Acute Infection

          -  Smoking

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill Wecht, EdD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Bronx</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Bronx</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Handrakis JP, DeMeersman RE, Rosado-Rivera D, LaFountaine MF, Spungen AM, Bauman WA, Wecht JM. Effect of hypotensive challenge on systemic hemodynamics and cerebral blood flow in persons with tetraplegia. Clin Auton Res. 2009 Feb;19(1):39-45. doi: 10.1007/s10286-008-0496-6. Epub 2008 Oct 11.</citation>
    <PMID>18850311</PMID>
  </results_reference>
  <results_reference>
    <citation>Wecht JM, Rosado-Rivera D, Jegede A, Cirnigliaro CM, Jensen MA, Kirshblum S, Bauman WA. Systemic and cerebral hemodynamics during cognitive testing. Clin Auton Res. 2012 Feb;22(1):25-33. doi: 10.1007/s10286-011-0139-1. Epub 2011 Jul 27.</citation>
    <PMID>21792728</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2005</study_first_submitted>
  <study_first_submitted_qc>November 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2005</study_first_posted>
  <results_first_submitted>September 12, 2013</results_first_submitted>
  <results_first_submitted_qc>May 21, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 23, 2014</results_first_posted>
  <last_update_submitted>May 21, 2014</last_update_submitted>
  <last_update_submitted_qc>May 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood Pressure, Low</keyword>
  <keyword>Hypotension, Postural</keyword>
  <keyword>Injuries, Spinal Cord</keyword>
  <keyword>Spinal Cord Transection</keyword>
  <keyword>Spinal Cord Trauma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Hypotension, Orthostatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment has been completed.</recruitment_details>
      <pre_assignment_details>All subjects recruited completed all testing procedures.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Subjects With Spinal Cord Injury (SCI)</title>
          <description>Subjects with SCI underwent a 45 degree head-up tilt maneuver to lower blood pressure and measure cerebral blood flow with and without enalaprilat (1.25 mg).</description>
        </group>
        <group group_id="P2">
          <title>Subjects Without SCI (Non-SCI)</title>
          <description>Subjects without SCI (non-SCI) underwent a 45 degree head-up tilt maneuver to lower blood pressure and measure cerebral blood flow with and without enalaprilat (1.25 mg).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subjects With Spinal Cord Injury</title>
          <description>Subjects with spinal cord injury underwent a 45 degree head-up tilt maneuver to lower blood pressure and monitor cerebral blood flow on 2 study visits. The first visit subject underwent the head-up tilt maneuver without drug and on the second visits subject underwent the head-up tilt maneuver following oral administration of an angiotensin converting enzyme inhibitor (ACE: 1.25 mg enalaprilat).</description>
        </group>
        <group group_id="B2">
          <title>Non-spinal Cord Injured Subjects</title>
          <description>Non-spinal cord injured subjects underwent a 45 degree head-up tilt maneuver to lower blood pressure and monitor cerebral blood flow on 2 study visits. The first visit subject underwent the head-up tilt maneuver without drug and on the second visits subject underwent the head-up tilt maneuver following oral administration of an angiotensin converting enzyme inhibitor (ACE: 1.25 mg enalaprilat).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="11"/>
                    <measurement group_id="B2" value="35" spread="12"/>
                    <measurement group_id="B3" value="39" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Systolic Blood Pressure</title>
        <description>Systolic blood pressure during head-up tilt in subjects with spinal cord injury without drug intervention</description>
        <time_frame>acute testing</time_frame>
        <population>convenience sample</population>
        <group_list>
          <group group_id="O1">
            <title>ARM 1</title>
            <description>45 degree head-up tilt to lower blood pressure and measure cerebral blood flow in subjects with spinal cord injury without drug</description>
          </group>
          <group group_id="O2">
            <title>ARM 2</title>
            <description>45 degree head-up tilt to lower blood pressure and measure cerebral blood flow in able-bodied control subjects without drug</description>
          </group>
          <group group_id="O3">
            <title>ARM 3</title>
            <description>45 degree head-up tilt to lower blood pressure and measure cerebral blood flow in subjects with spinal cord injury following intravenous administration of an angiotensin converting enzyme inhibitor (1.25 mg enalaprilat).</description>
          </group>
          <group group_id="O4">
            <title>ARM 4</title>
            <description>45 degree head-up tilt to lower blood pressure and measure cerebral blood flow in able-bodied control subjects following intravenous administration of an angiotensin converting enzyme inhibitor (1.25 mg enalaprilat).</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>Systolic blood pressure during head-up tilt in subjects with spinal cord injury without drug intervention</description>
          <population>convenience sample</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123" spread="37"/>
                    <measurement group_id="O2" value="125" spread="15"/>
                    <measurement group_id="O3" value="119" spread="26"/>
                    <measurement group_id="O4" value="122" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebral Blood Flow</title>
        <description>Measurement of middle cerebral artery blood flow velocity supine and during head-up tilt</description>
        <time_frame>acute testing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ARM 1</title>
            <description>45 degree head-up tilt to lower blood pressure and measure cerebral blood flow in subjects with spinal cord injury without drug.</description>
          </group>
          <group group_id="O2">
            <title>ARM 2</title>
            <description>45 degree head-up tilt to lower blood pressure and measure cerebral blood flow in able-bodied control subjects without drug.</description>
          </group>
          <group group_id="O3">
            <title>ARM 3</title>
            <description>45 degree head-up tilt to lower blood pressure and measure cerebral blood flow in subjects with spinal cord injury following intravenous administration of an angiotensin converting enzyme inhibitor (1.25 mg enalaprilat).</description>
          </group>
          <group group_id="O4">
            <title>ARM 4</title>
            <description>45 degree head-up tilt to lower blood pressure and measure cerebral blood flow in able-bodied control subjects following intravenous administration of an angiotensin converting enzyme inhibitor (1.25 mg enalaprilat).</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebral Blood Flow</title>
          <description>Measurement of middle cerebral artery blood flow velocity supine and during head-up tilt</description>
          <units>cm/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.95" spread="8.71"/>
                    <measurement group_id="O2" value="42.52" spread="15.69"/>
                    <measurement group_id="O3" value="46.93" spread="7.66"/>
                    <measurement group_id="O4" value="37.38" spread="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ARM 1</title>
          <description>45 degree head-up tilt to lower blood pressure and measure cerebral blood flow in subjects with spinal cord injury.</description>
        </group>
        <group group_id="E2">
          <title>ARM 2</title>
          <description>45 degree head-up tilt to lower blood pressure and measure cerebral blood flow in able-bodied controls.</description>
        </group>
        <group group_id="E3">
          <title>ARM 3</title>
          <description>1.25 mg enalaprilat IV and 45 degree head-up tilt to lower blood pressure and measure cerebral blood flow in subjects with spinal cord injury.</description>
        </group>
        <group group_id="E4">
          <title>ARM 4</title>
          <description>1.25 mg enalaprilat IV and 45 degree head-up tilt to lower blood pressure and measure cerebral blood flow in able-bodied controls.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Did not assess carbon dioxide levels or the severity of spinal cord injury, which may have contributed to the results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jill M. Wecht; Principal Investigator</name_or_title>
      <organization>James J Peters VAMC</organization>
      <phone>718 584-9000 ext 3122</phone>
      <email>JM.Wecht@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

